Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01960686 · ClinicalTrials.gov registry record · Phase 2
RSV F Dose-Ranging Study in Women
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 720
- Enrollment target
NCT01960686 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 720 participants.
The verdict
NCT01960686, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 720 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of multiple formulations of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy women of child-bearing age.
Interventions
- BIOLOGICAL Low dose RSV F Antigen
- BIOLOGICAL High dose RSV F Antigen
- BIOLOGICAL Dose 1 of Aluminum Adjuvant
- BIOLOGICAL Dose 2 of Aluminum Adjuvant
- BIOLOGICAL Dose 3 of Aluminum Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01960686
The ClinicalTrials.gov registry entry for NCT01960686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Low dose RSV F Antigen is the first listed.
NCT01960686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01960686 about?
NCT01960686 is a clinical study titled "RSV F Dose-Ranging Study in Women". The purpose of this study is to evaluate the immunogenicity and safety of multiple formulations of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy women of child-bearing age.
What is the current status of trial NCT01960686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 720 participants. The study started on 2013-10. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01960686?
The interventions under investigation include: Low dose RSV F Antigen (BIOLOGICAL), High dose RSV F Antigen (BIOLOGICAL), Dose 1 of Aluminum Adjuvant (BIOLOGICAL), Dose 2 of Aluminum Adjuvant (BIOLOGICAL), Dose 3 of Aluminum Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01960686?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.